• Mashup Score: 2

    During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Katja Weisel, University Medical Center Hamburg-Eppendorf, Hamburg, DE. We asked, Which therapies are most frequently used in triple-exposed patients with multiple myeloma (MM)?

    Tweet Tweets with this article
    • ⏰ In case you missed it ⏰ During #EBMT21, the MM Hub was pleased to speak with Katja Weisel, @uni_tue. We asked, Which therapies are most frequently used in triple-exposed patients with multiple #myeloma❓ #mmsm https://t.co/F7sbdXu4BS

  • Mashup Score: 1

    During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Katja Weisel, University Medical Center Hamburg-Eppendorf, Hamburg, DE. We asked, Which therapies are most frequently used in triple-exposed patients with multiple myeloma (MM)?

    Tweet Tweets with this article
    • ⌛ Catch up on this ⌛ During #EBMT21, the @MM_Hub was pleased to speak with Katja Weisel, @uni_tue. We asked, Which therapies are most frequently used in triple-exposed patients with multiple #myeloma? https://t.co/F7sbdXu4BS #mmsm

  • Mashup Score: 1

    Mobilized peripheral blood stem cells on the bone marrow are important for a successful autologous hematopoietic cell transplantation (auto-HCT). As such, collecting sufficient numbers of CD34+ cells is critical for a robust hematopoietic recovery and sustained engraftment.

    Tweet Tweets with this article
    • ⌛ In case you missed it ⌛ This retrospective study reports the outcomes of salvage auto-HSCT performed with remobilized stem cells, and it is associated with acceptable NRM and relapse incidence in multiple #myeloma. 📚 Read more here 👇 #EBMT21 #mmsm https://t.co/Butr4kCnah

  • Mashup Score: 0

    During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Laurent Garderet, Hôpital Pitié-Salpêtrière, Paris, FR. We asked, Is it safe to perform ASCT in patients with renal insufficiency?

    Tweet Tweets with this article
    • During #EBMT21, the @MM_Hub was pleased to speak with Laurent Garderet, @HopPitieSalpe. We asked, Is it safe to perform ASCT in patients with renal insufficiency? https://t.co/RTqucTTO5R #mmsm

  • Mashup Score: 0

    Therapy-related myeloid neoplasm (t-MN) is a secondary malignancy that can occur after being exposed to chemotherapy. 70% of t-MN cases appear 5–7 years after being treated with an alkylating agent, while the other 30% are diagnosed 2–3 years after treatment with topoisomerase II inhibitors (e.g., anthracyclines, etoposide).

    Tweet Tweets with this article
    • ⏰ Catch up on this Due to poor prognosis, patients with therapy-related #MDS and #AML are candidates for allogeneic #HSCT, but is it effective? 👉https://t.co/Qc1EepDVWQ 👈 #EBMT21 #leusm #AMLsm

  • Mashup Score: 0

    During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR. We asked, Is Isa+Kd efficacious in patients who have received prior autologous stem cell transplant (ASCT)?

    Tweet Tweets with this article
    • ⏰ In case you missed it 📹 #EBMT21 | Is Isa+Kd efficacious in patients who have received prior autologous stem cell transplant (ASCT)? Watch the @MM_Hub interview with Mohamad Mohty, @mohty_EBMT, @HopSaintAntoine, to find out 👇https://t.co/yM8Fiie2lI

  • Mashup Score: 0

    During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to Eliana Ruggiero, IRCCS Ospedale San Raffaele, Milan, IT. We asked, How can CRISPR be used for adoptive T-cell therapy in AML?

    Tweet Tweets with this article
    • 👀 Have you seen this? During #EBMT21, the @AML_Hub spoke to Eliana Ruggiero, @SanRaffaeleMI. We asked, How can CRISPR be used for adoptive T-cell therapy in #AML? 👉 https://t.co/56MxM8h9ic 👈 #Leusm #Leukemia #AMLsm https://t.co/0SOd2WLuJr

  • Mashup Score: 0

    During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to Norbert Vey, Institut Paoli-Calmettes, Marseille, FR. We asked, What challenges arise in the management of AML in complete remission?

    Tweet Tweets with this article
    • 🔔 In case you missed it! 👀 During #EBMT21, the @AML_Hub was pleased to speak to @norbert_vey, @paoli_calmettes. We asked, What challenges arise in the management of #AML in complete remission? 👉 https://t.co/9qxUCPsDQs 👈 #Leusm #Leukemia #AMLsm @TheEBMT https://t.co/J0zucKG73C